ArrayExpress Uploaderarrayexpress_sidhumanFL_ResponderFL_ResponderFL_Non_responderFL_Non_responderFL_Non_responderFL_ResponderFL_ResponderFL_ResponderFL_ResponderFL_Non_responderFL_Non_responderFL_Non_responderFL_Non_responder, BV_ResponderFL_Non_responderFL_Non_responderFL_Non_responder, BV_Non_reponderFL_Responder, BV_Non_reponderFL_Responder, BV_ResponderFL_Non_responderFL_Non_responder, BV_ResponderFL_Non_responderFL_Non_responderFL_Non_responderFL_ResponderFL_Non_responderFL_Non_responderFL_ResponderFL_Non_responderFL_Non_responder, BV_Non_reponderFL_Non_responderFL_Non_responderFL_Non_responderFL_Responder, BV_Non_reponderFL_Non_responder, BV_ResponderFL_Non_responderFL_ResponderFL_Responder, BV_Non_reponderFL_Responder, BV_Non_reponderFL_Non_responder, BV_ResponderFL_Responder, BV_Non_reponder355004The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received modified...E-GEOD-19860/profile/8773/arrayexpressuploader140cancercolorectal cancergenomelineDec.12, 2014FalseE-GEOD-19860_A-AFFY-44prediction-of-response-to-folfoxPrediction of response to FOLFOXSep.15, 2014The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received modified FOLFOX6. Responders and nonresponders were determined based on the best observed response at the end of the first-line treatment, mFOLFOX6. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133. Colorectal cancer patients who had undergone surgical resection of colorectal cancer were studied. To identify molecular signatures to predict response to mFOLFOX6 regimen, gene expression profiles were compared between Reponder and Non-responder. Some patients are overlapped with Bevacizumab therapy.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-19860http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-19860/samples/